Human MAGP-2 Protein, Fc Tag
分子別名(Synonym)
MAGP2
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human MAGP-2, Fc Tag (MA2-H5254) is expressed from human 293 cells (HEK293). It contains AA Ile 22 - Leu 173 (Accession # Q13361-1).
Predicted N-terminus: Ile 22
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a Fc tag at the C-terminus. This protein contains a furin convertase cleavage site, 149-RRLR-152, and will be partially processed into N and C-terminal fragment with calculated MW of 43.7 kDa and 29.1 kDa respectively. The protein migrates as 55-66 kDa and 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
MAGP-2(微纖維相關(guān)糖蛋白2),也稱為MFAP5(微纖維關(guān)聯(lián)蛋白5),是MFAP蛋白家族中分泌的細(xì)胞相關(guān)25kDa哺乳動(dòng)物成員。MAGP-1和MAGP-2都通過富含半胱氨酸的結(jié)合結(jié)構(gòu)域結(jié)合并共價(jià)交聯(lián)纖維蛋白-1和-2。在功能上,MAGP-2 RGD基序與整合素αvβ3結(jié)合,允許細(xì)胞附著在微纖維上。MAGP2被認(rèn)為有助于微纖維組裝并誘導(dǎo)彈性蛋白纖維形成。通過與EGF重復(fù)序列的結(jié)合,MAGP 2介導(dǎo)Jagged1的金屬蛋白酶依賴性釋放和Notch細(xì)胞外結(jié)構(gòu)域的金屬蛋白酶非依賴性釋放。在內(nèi)皮細(xì)胞中,MAGP-2通過抑制Notch信號傳導(dǎo)、與整合素αvβ3結(jié)合(然后增強(qiáng)VEGF信號傳導(dǎo))和/或增強(qiáng)內(nèi)皮細(xì)胞對FGF堿性和EGF的反應(yīng)來促進(jìn)血管生成發(fā)芽。在卵巢癌癥中,MAGP-2的表達(dá)與癌癥細(xì)胞存活、微血管密度增加和預(yù)后不良有關(guān)。
關(guān)鍵字: MAGP2;MAGP2蛋白;MAGP2重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。